Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Dec 1;272(2):327-31.
doi: 10.1042/bj2720327.

Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function

Affiliations

Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function

M M Whalen et al. Biochem J. .

Abstract

Membranes from highly purified natural killer (NK) cells were ADP-ribosylated by treatment with cholera toxin (CTX). CTX resulted in a single band of specific 32P incorporation at Mr 43,600. CTX treatment of intact NK cells caused a 9-fold increase in cyclic AMP (cAMP) concentrations. Pretreatment of NK cells with CTX diminished their ability to lyse K562 tumour cells by up to 79%. Forskolin treatment elevated NK cell cAMP levels 8-fold and decreased lysis of K562 cells by up to 45%. Adrenaline and isoprenaline (isoproterenol) both inhibited lysis of K562 cells by approx. 35% and elevated cAMP by at least 2.5-fold, and their inhibition of lysis was reversed by propranolol. These data suggest that the stimulatory guanine-nucleotide-binding protein GS coupled to beta-adrenergic receptors is involved in transducing signals which inhibit NK cell lysis of tumour cells. CTX and forskolin also diminish the ability of NK cells to bind K562 cells (binding is necessary for lysis). This suggests that the NK-cell receptor(s) for the tumour cell may be altered as a consequence of cAMP-mediated events or by activation of GS.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol. 1979 Oct;123(4):1445-50 - PubMed
    1. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3050-4 - PubMed
    1. J Biol Chem. 1980 Feb 25;255(4):1252-8 - PubMed
    1. J Immunol. 1981 Jun;126(6):2129-35 - PubMed
    1. Int J Cancer. 1981 Jan 15;27(1):29-36 - PubMed

Publication types

MeSH terms